Bitdeer Technologies Group vs Vertex Pharmaceuticals Incorporated — how do they compare? Bitdeer Technologies Group trades at $8.9 (market cap $2.36B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 56.9× Bitdeer Technologies Group's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BTDR | VRTX | |
|---|---|---|
Market Cap | $2.36B | $134.25B |
Sector | Technology | Health |
52-Week High | $25.90 | $529.65 |
52-Week Low | $7.28 | $376.62 |
Enterprise Value | $3.85B | $128.37B |
Trailing returns across standard periods
Latest headlines on both assets
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →